MedPath

Fetal brain imaging in fetuses at high risk of acquired anomalies

Completed
Conditions
acquired fetal brain damage
hypoxic ischemic infectious encephalopathy
10047438
10010335
10026908
Registration Number
NL-OMON35261
Lead Sponsor
Vrije Universiteit Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
400
Inclusion Criteria

zwangeren waarbij een infectie is aangetoond (toxoplasmose, cytomegalie), trauma hebben ondergaan of trombocytopenie (allo-immuun) of bij de foetus een groeirestrictie is aangetoond onder de 10de percentiel voor 30 weken zwangerschapsduur, hydrops (verdacht voor anemie, arythmie, parvo virus infectie of hydrothorax), monochriale tweeling, echoscopische hersenbevindingen passend bij verkregen afwijking.

Exclusion Criteria

age below 18 years
serious language or communication barrier
pacemaker (with respect to MRI)
familial chromosomal, syndromal or metabolic abnormality
confirmed chromosomal abnormality
suspected syndromal or metabolic abnormality

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>What is the added value of transvaginal ultrasound or MRI to abdominal<br /><br>ultrasound in a fetus at thig risk of deveoping brain damage in the second and<br /><br>third trimester of pregnancy.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>What is the prevalence of changes visible on antenatal ultrasound in the areas<br /><br>in the brain that are prone to hypoxic ischemic damage after birth.<br /><br>What is the evolution of these changes over time before and after birth.<br /><br>Which antenatal ultrasound findings are associated with abnormal neurological<br /><br>development until five years of age.<br /><br>At which gestational age can brain damage best be determined with<br /><br>transabdominal and transvaginal ultrasound and MRI.<br /><br>Which brain imaging procedures have the best predictive value for the<br /><br>neurological outcome at two and five uears of age and how are they related<br /><br>cost-effectively.</p><br>
© Copyright 2025. All Rights Reserved by MedPath